|
Inflammatory Bowel Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aberrant interferon gamma (IFNγ) expression is associated with the pathogenesis of numerous autoimmune- and inflammatory disorders, including inflammatory bowel diseases (IBD).
|
29416538 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Pediatric patients with IBD on long-term treatment with infliximab had an adequate interferon-γ response to mitogen and a low indeterminate rate when assessed with the QuantiFERON-TB Gold In-Tube test.
|
29562270 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
There was a retrospective review of all IBD patients diagnosed with LTBI following a tuberculin skin test (TST) and/or interferon gamma release assay (IGRA) and who received biologic therapy between 2002 and 2016.
|
29718223 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Screening for latent tuberculosis infection in patients with inflammatory bowel disease: Can interferon-gamma release assays replace the tuberculin skin test?
|
29755013 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Serum interleukin (IL)-10, IL-17A, IL-6, and interferon-γ were significantly higher in patients with IBD with IGF-1 z scores in the lowest quartile (P < 0.05).
|
29901552 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The inflammatory response to IBD was assessed by measuring the expression of myeloperoxidase, interleukin (IL)-17 (IL-17), interferon-γ (IFN-γ), IL-10, tumor necrosis factor-α (TNF-α), and transforming growth factor-β (TGF-β).
|
29973876 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Both animal and human studies suggest that bioactive functional foods can ameliorate IBD by downregulating the pro-inflammatory signaling pathways, such as nuclear factor κB, STAT1, STAT6, and pro-inflammatory cytokines, including IL-1β, IL-4, IL-6, COX-2, TNF-α, and interferon γ.
|
29991873 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-17-producing Th17 cells and IFN-γ and IL-17 double-producing Th1/17 cells have been identified as the pathogenic cells in inflammatory bowel disease (IBD).
|
30121880 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The present study reports (for the first time) significant associations between SNPs within the IFN-γ and IL-2 genes and IBD.
|
30134230 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The up-regulated expression of the Ca<sup>2+</sup>-activated K⁺ channel K<sub>Ca</sub>3.1 in inflammatory CD4⁺ T cells has been implicated in the pathogenesis of inflammatory bowel disease (IBD) through the enhanced production of inflammatory cytokines, such as interferon-γ (IFN-γ).
|
30262728 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
T cells producing IFNγ play a pathogenic role in the development of inflammatory bowel disease (IBD).
|
30333822 |
2018 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil.
|
30673986 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Our studies indicate that IFN-γ dose and time-dependently reduces normal HISMC contractility, motility and proliferation which may contribute to dysmotility observed in GI inflammatory disorders and that IFN-γ therapeutics might restore normal HISMC contractility impaired in IBD.
|
30825545 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of IBD LPMC with NPD-0414-2 and NPD-0414-24 reduced IFN-γ and increased IL-22 transcripts, and these effects were abrogated by CH223191, a specific inhibitor of AhR interaction with its ligands.
|
31031628 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-10 signaling in dendritic cells controls IL-1β-mediated IFNγ secretion by human CD4<sup>+</sup> T cells: relevance to inflammatory bowel disease.
|
31417161 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Comparing the change of the variables indicated a significant decrease in fecal calprotectin (P < 0.001), Mayo score (P < 0.001), ESR (P < 0.001), INF-γ (P < 0.001), IL-6 (P < 0.001), waist circumference (P = 0.02), Diastolic Blood Pressure (DBP) (P < 0.001), and Systolic Blood Pressure (SBP) (P < 0.001) and a significant increase in TGF-β (P < 0.001) and Inflammatory Bowel Disease Questionnaire-Short form (IBDQ-9) score (P < 0.001) in the GF and FO groups compared to the control.
|
31519285 |
2019 |
|
Inflammatory Bowel Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on these considerations, we analyzed the vessel-directed pathogenic functions of IFN-γ and found that it drives IBD pathogenesis through vascular barrier disruption.
|
31566580 |
2019 |